Eicosanoids in human heart failure: pilot study of plasma epoxyeicosatrienoic and dihydroxyeicosatrienoic acid levels

Petr Kala; Tomas Hnat; Karolina Padrova; Karel Kotaška; Josef Veselka

doi:10.5114/aoms/159313

Eicosanoids in human heart failure: pilot study of plasma epoxyeicosatrienoic and dihydroxyeicosatrienoic acid levels

Arch Med Sci. 2023 Feb 6;19(2):513-517. doi: 10.5114/aoms/159313. eCollection 2023.

Authors

Petr Kala^{1

2}, Tomas Hnat¹, Karolina Padrova³, Karel Kotaška³, Josef Veselka¹

Affiliations

¹ Department of Cardiology, University Hospital Motol and 2 Faculty of Medicine, Charles University, Prague, Czech Republic.
² Center of Experimental Medicine, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
³ Department of Medical Chemistry and Biochemistry, University Hospital Motol and 2 Faculty of Medicine, Charles University, Prague, Czech Republic.

Abstract

Introduction: The role of eicosanoids, metabolites of arachidonic acid with cardio-renal activity, remains unclear in human heart failure (HF).

Methods: We enrolled 50 patients with HF to measure plasma 14,15-EET and 14,15-DHET levels using commercial ELISA kits and compared them with 25 age- and sex-matched controls.

Results: Both of the measured eicosanoids were significantly higher in the HF group: 14,15-EET (91.3 ±25.7 ng/ml vs. 64.95 ±35.4 ng/ml) and 14,15-DHET (10.58 ±2.06 ng/ml vs. 9.07 ±1.60 ng/ml), p for both < 0.001.

Conclusions: We found that peripheral plasma eicosanoid (14,15-EET, 14,15-DHET) levels are raised in patients with HF compared to age- and sex-matched controls.

Keywords: dihydroxyeicosatrienoic acid; eicosanoids; epoxyeicosatrienoic acid; heart failure.